Please check your internet connection and try again.
# Clobazam (Oral)
## Overview
Clobazam is a benzodiazepine with anticonvulsant properties. It is a Schedule IV controlled substance.
## Primary Indications
* Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years and older.
* Off-label uses include other seizure types and anxiety disorders.
## Adult Dosing
* **LGS:** Initial dose is typically 5 mg twice daily. Increase by 5-10 mg every week based on clinical response and tolerability, not to exceed a maximum of 20 mg twice daily.
* **Other indications (off-label):** Dosing varies significantly; consult specific guidelines.
## Pediatric Dosing
* **LGS (2 to less than 10 years):** Initial dose is typically 5 mg twice daily. Increase by 2.5-5 mg every week based on clinical response and tolerability, not to exceed a maximum of 10 mg twice daily.
* **LGS (10 years and older):** Same as adult dosing (initial 5 mg twice daily, max 20 mg twice daily).
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. No specific dose adjustment recommendations, but reduced doses may be warranted.
* **Renal Impairment:** Use with caution. No specific dose adjustment recommendations, but reduced doses may be warranted.
## Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
* Severe hepatic impairment.
## Adverse Effects
* **Common:** Somnolence, constipation, decreased appetite, irritability, aggression, respiratory tract infections, pneumonia.
* **Serious:** Suicidal behavior and ideation, severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), respiratory depression, dependence, withdrawal symptoms, paradoxical reactions.
## Key Drug Interactions
* **CNS Depressants (e.g., opioids, alcohol, other sedatives):** Increased risk of profound sedation, respiratory depression, coma, and death. Use with extreme caution and consider reduced doses of one or both agents.
* **CYP3A4 Inhibitors (e.g., ketoconazole, fluconazole):** May increase clobazam concentrations.
* **CYP3A4 Inducers (e.g., carbamazepine, phenytoin, rifampin):** May decrease clobazam concentrations.
* **Antiepileptic Drugs (AEDs):** Potential for additive CNS depression. Monitor for efficacy and toxicity.
## Monitoring
* Seizure frequency and severity.
* Signs of somnolence and sedation, especially when initiating or increasing dose.
* Suicidal ideation and behavior.
* Signs of severe skin reactions.
* Respiratory status.
* Signs of withdrawal upon discontinuation.
## Clinical Pearls
* Clobazam is a Schedule IV controlled substance. Prescribe and dispense accordingly.
* Dosing should be individualized based on clinical response and tolerability.
* Do not abruptly discontinue clobazam due to the risk of withdrawal symptoms; taper gradually.
* Patients and caregivers should be advised of the risk of suicidal thoughts and behaviors and to report any such changes immediately.
* Monitor for increased seizure activity or status epilepticus, especially with dose changes or in patients with concomitant medications affecting seizure threshold.
---
*Disclaimer: This information is intended for clinical use and does not replace comprehensive drug information resources. Always verify current prescribing information and consult with a qualified healthcare provider before making any treatment decisions.*
